Morgan Stanley Accelerate Diagnostics, Inc Transaction History

Morgan Stanley

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.64 - $1.03 $142,348 - $229,091	-222,419 Reduced 90.88%	22,322 $18,000
Q1 2023 May 15, 2023	SELL	$0.46 - $0.77 $5,864 - $9,815	-12,748 Reduced 4.95%	244,741 $171,000
Q4 2022 Feb 14, 2023	BUY	$0.51 - $17.1 $112,529 - $3.77 Million	220,646 Added 598.88%	257,489 $182,000
Q3 2022 Nov 14, 2022	SELL	$1.01 - $17.0 $47,374 - $797,385	-46,905 Reduced 56.01%	36,843 $57,000
Q2 2022 Oct 27, 2022	SELL	$0.54 - $1.41 $47,833 - $124,897	-88,580 Reduced 51.4%	83,748 $83,000
Q2 2022 Aug 15, 2022	SELL	$0.54 - $1.41 $47,833 - $124,897	-88,580 Reduced 51.4%	83,748 $83,000
Q1 2022 Oct 27, 2022	BUY	$1.4 - $5.15 $124,011 - $456,187	88,580 Added 105.77%	172,328 $248,000
Q1 2022 May 13, 2022	BUY	$1.4 - $5.15 $32,286 - $118,769	23,062 Added 15.45%	172,328 $248,000
Q4 2021 Feb 14, 2022	BUY	$4.27 - $6.97 $472,261 - $770,882	110,600 Added 286.04%	149,266 $780,000
Q3 2021 Nov 15, 2021	BUY	$5.31 - $8.25 $205,316 - $318,994	38,666 New	38,666 $226,000

549K

Ticker AXDX
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 99,059,904
Market Cap $191M
Description
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious ...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.